{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T11:16:55Z","timestamp":1788261415366,"version":"build-2803163510"},"reference-count":42,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,20]],"date-time":"2025-11-20T00:00:00Z","timestamp":1763596800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000057","name":"National Institute of General Medical Sciences","doi-asserted-by":"publisher","award":["3R16GM149204-02S1"],"award-info":[{"award-number":["3R16GM149204-02S1"]}],"id":[{"id":"10.13039\/100000057","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000025","name":"National Institute of Mental Health","doi-asserted-by":"publisher","award":["HHSN-271-2018-00023-C"],"award-info":[{"award-number":["HHSN-271-2018-00023-C"]}],"id":[{"id":"10.13039\/100000025","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008312","name":"California State University, Fullerton","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008312","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000001","name":"National Science Foundation","doi-asserted-by":"publisher","award":["CHE1726903"],"award-info":[{"award-number":["CHE1726903"]}],"id":[{"id":"10.13039\/100000001","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["U54 NS127758"],"award-info":[{"award-number":["U54 NS127758"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000066","name":"National Institute of Environmental Health Sciences","doi-asserted-by":"publisher","award":["R35 ES030443"],"award-info":[{"award-number":["R35 ES030443"]}],"id":[{"id":"10.13039\/100000066","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic & Medicinal Chemistry"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.bmc.2025.118495","type":"journal-article","created":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T05:10:18Z","timestamp":1763701818000},"page":"118495","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Polynitrogen-containing compounds as multi-target sEH\/FAAH inhibitors: Structure-activity relationship and pharmacological studies"],"prefix":"10.1016","volume":"133","author":[{"given":"Amanda","family":"Tsang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cassandra","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuel","family":"Berumen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leah","family":"Duong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"Gomez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shelby","family":"Seely","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex","family":"Salgado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adim","family":"Rai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jo","family":"Vistosa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edith Morales","family":"Munoz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcos E.","family":"Ortega","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christophe","family":"Morisseau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruce D.","family":"Hammock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jake E.","family":"Zuckerman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Yount","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Davin G.","family":"Piercey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ram","family":"Kandasamy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stevan","family":"Pecic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.bmc.2025.118495_bb0005","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1517\/17460440903018857","article-title":"Fatty acid amide hydrolase as a potential therapeutic target for the treatment of pain and CNS disorders","volume":"4","author":"Ahn","year":"2009","journal-title":"Expert Opin Drug Discov"},{"issue":"30","key":"10.1016\/j.bmc.2025.118495_bb0010","doi-asserted-by":"crossref","first-page":"E6034","DOI":"10.1073\/pnas.1610325114","article-title":"Anti-inflammatory \u03c9-3 endocannabinoid epoxides","volume":"114","author":"McDougle","year":"2017","journal-title":"Proc Natl Acad Sci"},{"issue":"4","key":"10.1016\/j.bmc.2025.118495_bb0015","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/j.chembiol.2009.02.013","article-title":"Discovery and characterization of a highly selective FAAH inhibitor that reduces inflammatory pain","volume":"16","author":"Ahn","year":"2009","journal-title":"Chem Biol"},{"issue":"29","key":"10.1016\/j.bmc.2025.118495_bb0020","doi-asserted-by":"crossref","first-page":"10821","DOI":"10.1073\/pnas.0401292101","article-title":"Functional disassociation of the central and peripheral fatty acid amide signaling systems","volume":"101","author":"Cravatt","year":"2004","journal-title":"Proc Natl Acad Sci"},{"issue":"1","key":"10.1016\/j.bmc.2025.118495_bb0025","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1111\/j.1527-3458.2006.00021.x","article-title":"Pharmacological profile of the selective FAAH inhibitor KDS-4103 (URB597)","volume":"12","author":"Piomelli","year":"2006","journal-title":"CNS Drug Rev"},{"issue":"10","key":"10.1016\/j.bmc.2025.118495_bb0030","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1038\/nrd2875","article-title":"Soluble epoxide hydrolase as a therapeutic target for cardiovascular diseases","volume":"8","author":"Imig","year":"2009","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.bmc.2025.118495_bb0035","doi-asserted-by":"crossref","first-page":"61","DOI":"10.2147\/JPR.S241893","article-title":"Inhibition of the soluble epoxide hydrolase as an analgesic strategy: a review of preclinical evidence","volume":"14","author":"Wang","year":"2021","journal-title":"J Pain Res"},{"issue":"7","key":"10.1016\/j.bmc.2025.118495_bb0040","doi-asserted-by":"crossref","first-page":"9074","DOI":"10.1096\/fj.202000415R","article-title":"Soluble epoxide hydrolase inhibitor, TPPU, increases regulatory T cells pathway in an arthritis model","volume":"34","author":"Trindade-da-Silva","year":"2020","journal-title":"FASEB J"},{"key":"10.1016\/j.bmc.2025.118495_bb0045","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.phrs.2015.04.001","article-title":"Peripheral FAAH and soluble epoxide hydrolase inhibitors are synergistically antinociceptive","volume":"97","author":"Sasso","year":"2015","journal-title":"Pharmacol Res"},{"key":"10.1016\/j.bmc.2025.118495_bb0050","doi-asserted-by":"crossref","first-page":"205","DOI":"10.3389\/fphar.2015.00205","article-title":"Multi-target pharmacology: possibilities and limitations of the \"skeleton key approach\" from a medicinal chemist perspective","volume":"6","author":"Talevi","year":"2015","journal-title":"Front Pharmacol"},{"issue":"1","key":"10.1016\/j.bmc.2025.118495_bb0055","doi-asserted-by":"crossref","first-page":"2","DOI":"10.2174\/1570159X113116660047","article-title":"Multi-target-directed ligands and other therapeutic strategies in the search of a real solution for Alzheimer\u2019s disease","volume":"12","author":"Agis-Torres","year":"2014","journal-title":"Curr Neuropharmacol"},{"issue":"2","key":"10.1016\/j.bmc.2025.118495_bb0060","doi-asserted-by":"crossref","first-page":"113","DOI":"10.3390\/ph7020113","article-title":"From single target to multitarget\/network therapeutics in Alzheimer's therapy","volume":"7","author":"Zheng","year":"2014","journal-title":"Pharmaceuticals-Base"},{"issue":"1","key":"10.1016\/j.bmc.2025.118495_bb0065","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1080\/14756366.2020.1862101","article-title":"Novel oxindole\/benzofuran hybrids as potential dual CDK2\/GSK-3\u03b2 inhibitors targeting breast cancer: design, synthesis, biological evaluation, and in silico studies","volume":"36","author":"Eldehna","year":"2021","journal-title":"J. Enzyme Inhib. Med. Chem."},{"key":"10.1016\/j.bmc.2025.118495_bb0070","doi-asserted-by":"crossref","unstructured":"Choi, S. Y.; Jung, J.; Han, J. H.; Shin, J.; Moon, J.-W.; Song, S. H.; You, D.; Hwang, J. J.; Kim, C.-S. PD32\u201308 SYNERGISTIC ANTICANCER EFFECT OF COMBINATION TREATMENT WITH MEK INHIBITOR AND PI3K \/MTOR DUAL INHIBITOR IN CASTRATION-RESISTANT PROSTATE CANCER IN VIVO AND EX VIVO. The Journal of Urology 2016, 195 (4, Supplement), e763. Doi:https:\/\/doi.org\/10.1016\/j.juro.2016.02.684.","DOI":"10.1016\/j.juro.2016.02.684"},{"key":"10.1016\/j.bmc.2025.118495_bb0075","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2020.104165","article-title":"Development of multitarget inhibitors for the treatment of pain: design, synthesis, biological evaluation and molecular modeling studies","volume":"103","author":"Wilt","year":"2020","journal-title":"Bioorg Chem"},{"key":"10.1016\/j.bmc.2025.118495_bb0080","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmc.2021.116507","article-title":"Further exploration of the structure-activity relationship of dual soluble epoxide hydrolase\/fatty acid amide hydrolase inhibitors","volume":"51","author":"Wilt","year":"2021","journal-title":"Bioorg Med Chem"},{"key":"10.1016\/j.bmc.2025.118495_bb0085","doi-asserted-by":"crossref","DOI":"10.1016\/j.prostaglandins.2022.106702","article-title":"Structure-activity relationship studies of benzothiazole-phenyl analogs as multi-target ligands to alleviate pain without affecting normal behavior","volume":"164","author":"Angelia","year":"2023","journal-title":"Prostaglandins Other Lipid Mediat"},{"key":"10.1016\/j.bmc.2025.118495_bb0090","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmc.2025.118112","article-title":"Structure-activity relationship studies and pharmacological evaluation of 4-phenylthiazoles as dual soluble epoxide hydrolase\/fatty acid amide hydrolase inhibitors","volume":"121","author":"Yuan","year":"2025","journal-title":"Bioorg Med Chem"},{"issue":"11","key":"10.1016\/j.bmc.2025.118495_bb0095","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2024.e32262","article-title":"Quinolinyl-based multitarget-directed ligands with soluble epoxide hydrolase and fatty acid amide hydrolase inhibitory activities: synthetic studies and pharmacological evaluations","volume":"10","author":"Angelia","year":"2024","journal-title":"Heliyon"},{"key":"10.1016\/j.bmc.2025.118495_bb0100","article-title":"Synthesis and evaluation of isoquinolinyl and pyridinyl-based dual inhibitors of fatty acid amide hydrolase and soluble epoxide hydrolase to alleviate orofacial hyperalgesia in the rat","volume":"42","author":"Carr","year":"2025","journal-title":"Biochem Biophys Rep"},{"issue":"10","key":"10.1016\/j.bmc.2025.118495_bb0105","doi-asserted-by":"crossref","first-page":"4369","DOI":"10.1021\/acs.jmedchem.7b00328","article-title":"Discovery of a hepatitis C virus NS5B Replicase palm site allosteric inhibitor (BMS-929075) advanced to phase 1 clinical studies","volume":"60","author":"Yeung","year":"2017","journal-title":"J Med Chem"},{"issue":"18","key":"10.1016\/j.bmc.2025.118495_bb0110","doi-asserted-by":"crossref","first-page":"4546","DOI":"10.1016\/j.bmcl.2014.07.071","article-title":"Fragment-based identification and optimization of a class of potent pyrrolo[2,1-f][1,2,4]triazine MAP4K4 inhibitors","volume":"24","author":"Wang","year":"2014","journal-title":"Bioorg Med Chem Lett"},{"issue":"1","key":"10.1016\/j.bmc.2025.118495_bb0115","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1039\/C9MD00396G","article-title":"Scaffold-hopping as a strategy to address metabolic liabilities of aromatic compounds","volume":"11","author":"Lazzara","year":"2020","journal-title":"RSC Med. Chem."},{"issue":"20","key":"10.1016\/j.bmc.2025.118495_bb0120","doi-asserted-by":"crossref","first-page":"8770","DOI":"10.1021\/jm3010724","article-title":"Discovery of 3-Cyclopropylmethyl-7-(4-phenylpiperidin-1-yl)-8-trifluoromethyl[1,2,4]triazolo[4,3-a]pyridine (JNJ-42153605): a positive allosteric modulator of the metabotropic glutamate 2 receptor","volume":"55","author":"Cid","year":"2012","journal-title":"J Med Chem"},{"issue":"9","key":"10.1016\/j.bmc.2025.118495_bb0125","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1016\/0006-2952(94)90520-7","article-title":"Utility of in vitro drug metabolism data in predicting in vivo metabolic clearance","volume":"47","author":"Brian Houston","year":"1994","journal-title":"Biochem Pharmacol"},{"issue":"21","key":"10.1016\/j.bmc.2025.118495_bb0130","doi-asserted-by":"crossref","first-page":"9824","DOI":"10.1021\/acs.jmedchem.9b01220","article-title":"The blood-brain barrier (BBB) score","volume":"62","author":"Gupta","year":"2019","journal-title":"J Med Chem"},{"issue":"5","key":"10.1016\/j.bmc.2025.118495_bb0135","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1111\/cbdd.13670","article-title":"Design, microwave-assisted synthesis, biological evaluation and molecular modeling studies of 4-phenylthiazoles as potent fatty acid amide hydrolase inhibitors","volume":"95","author":"Wilt","year":"2020","journal-title":"Chem Biol Drug Des"},{"issue":"2","key":"10.1016\/j.bmc.2025.118495_bb0140","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.bmcl.2012.11.084","article-title":"Synthesis and structure-activity relationship of piperidine-derived non-urea soluble epoxide hydrolase inhibitors","volume":"23","author":"Pecic","year":"2013","journal-title":"Bioorg Med Chem Lett"},{"issue":"2","key":"10.1016\/j.bmc.2025.118495_bb0145","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1517\/17425255.1.2.175","article-title":"Caco-2 cell permeability assays to measure drug absorption","volume":"1","author":"van Breemen","year":"2005","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"2\u20133","key":"10.1016\/j.bmc.2025.118495_bb0150","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/S0091-3057(01)00624-4","article-title":"Naloxone suppression and morphine enhancement of voluntary wheel-running activity in rats","volume":"70","author":"Sisti","year":"2001","journal-title":"Pharmacol Biochem Behav"},{"issue":"14","key":"10.1016\/j.bmc.2025.118495_bb0155","doi-asserted-by":"crossref","DOI":"10.3390\/molecules26144355","article-title":"Profiling the effects of repetitive morphine administration on motor behavior in rats","volume":"26","author":"Paul","year":"2021","journal-title":"Molecules"},{"key":"10.1016\/j.bmc.2025.118495_bb0160","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1016\/j.bbr.2016.10.024","article-title":"Analysis of inflammation-induced depression of home cage wheel running in rats reveals the difference between opioid antinociception and restoration of function","volume":"317","author":"Kandasamy","year":"2017","journal-title":"Behav Brain Res"},{"issue":"2","key":"10.1016\/j.bmc.2025.118495_bb0165","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.beproc.2004.12.006","article-title":"The reinforcing property and the rewarding aftereffect of wheel running in rats: a combination of two paradigms","volume":"68","author":"Belke","year":"2005","journal-title":"Behav Process"},{"issue":"2","key":"10.1016\/j.bmc.2025.118495_bb0170","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1124\/jpet.106.106377","article-title":"Preclinical assessment of candidate analgesic drugs: recent advances and future challenges","volume":"319","author":"Negus","year":"2006","journal-title":"J Pharmacol Exp Ther"},{"issue":"2&3","key":"10.1016\/j.bmc.2025.118495_bb0175","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1097\/FBP.0000000000000596","article-title":"\u201cReinventing the wheel\u201d to advance the development of pain therapeutics","volume":"32","author":"Kandasamy","year":"2021","journal-title":"Behav Pharmacol"},{"issue":"15","key":"10.1016\/j.bmc.2025.118495_bb0180","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.1055\/s-0032-1316737","article-title":"Some practical methods for the application of 5-Metallo-1-benzyl-1H-tetrazoles in synthesis","volume":"23","author":"Wiedemann","year":"2012","journal-title":"Synlett"},{"issue":"2","key":"10.1016\/j.bmc.2025.118495_bb0185","doi-asserted-by":"crossref","DOI":"10.1002\/zaac.202100333","article-title":"An improved synthesis of Bromotetrazole","volume":"648","author":"Wozniak","year":"2022","journal-title":"Z Anorg Allg Chem"},{"issue":"31","key":"10.1016\/j.bmc.2025.118495_bb0190","doi-asserted-by":"crossref","DOI":"10.1002\/chem.202400661","article-title":"Sequential, Electrochemical-photochemical synthesis of 1,2,4-Triazolo-[4,3-a]pyrazines","volume":"30","author":"Yount","year":"2024","journal-title":"Chemistry \u2013 A European Journal"},{"issue":"1","key":"10.1016\/j.bmc.2025.118495_bb0195","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.ab.2006.10.041","article-title":"Development of highly sensitive fluorescent assays for fatty acid amide hydrolase","volume":"363","author":"Huang","year":"2007","journal-title":"Anal Biochem"},{"issue":"1","key":"10.1016\/j.bmc.2025.118495_bb0200","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.ab.2005.03.041","article-title":"Fluorescent substrates for soluble epoxide hydrolase and application to inhibition studies","volume":"343","author":"Jones","year":"2005","journal-title":"Anal Biochem"},{"key":"10.1016\/j.bmc.2025.118495_bb0205","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.prostaglandins.2018.02.004","article-title":"Novel piperidine-derived amide sEH inhibitors as mediators of lipid metabolism with improved stability","volume":"136","author":"Pecic","year":"2018","journal-title":"Prostaglandins Other Lipid Mediat"},{"issue":"16","key":"10.1016\/j.bmc.2025.118495_bb0210","doi-asserted-by":"crossref","first-page":"3825","DOI":"10.1021\/jm070270t","article-title":"Orally bioavailable potent soluble epoxide hydrolase inhibitors","volume":"50","author":"Hwang","year":"2007","journal-title":"J Med Chem"}],"container-title":["Bioorganic & Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0968089625004365?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0968089625004365?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T08:40:24Z","timestamp":1781253624000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0968089625004365"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":42,"alternative-id":["S0968089625004365"],"URL":"https:\/\/doi.org\/10.1016\/j.bmc.2025.118495","relation":{},"ISSN":["0968-0896"],"issn-type":[{"value":"0968-0896","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Polynitrogen-containing compounds as multi-target sEH\/FAAH inhibitors: Structure-activity relationship and pharmacological studies","name":"articletitle","label":"Article Title"},{"value":"Bioorganic & Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bmc.2025.118495","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"118495"}}